Product Description
Levodropropizine 99291-25-5
AI Product Description
*The following content is generated by AI and is for reference only.
Levodropropizine is a non-opioid, centrally acting antitussive agent widely utilized in the management of cough associated with various respiratory conditions. Chemically known as 3-(2-methylphenoxy)propyl diethylamine, its molecular formula is C14H23NO2. The substance is identified by the CAS Registry Number 86079-35-6. Structurally, it belongs to the class of ether derivatives and functions primarily by inhibiting the cough reflex at the central level within the medulla oblongata, specifically without affecting respiratory drive or causing significant sedation.
The primary clinical application of Levodropropizine is the symptomatic relief of dry, non-productive coughs found in acute bronchitis, upper respiratory tract infections, and chronic obstructive pulmonary disease (COPD). Unlike traditional opioids such as codeine, this compound does not bind to opioid receptors, thereby eliminating risks of addiction, respiratory depression, and severe constipation. Its mechanism involves blocking sensory nerve endings in the airways and modulating the cough center in the brain, effectively suppressing the urge to cough while preserving normal mucociliary clearance. This makes it particularly suitable for pediatric and geriatric populations where safety profiles are paramount.
Pharmacokinetically, Levodropropizine exhibits rapid absorption following oral administration, reaching peak plasma concentrations within one to two hours. It undergoes extensive first-pass metabolism in the liver, producing active metabolites that contribute to its therapeutic efficacy. The drug is generally well-tolerated, with adverse effects being mild and infrequent, typically limited to transient gastrointestinal disturbances or dizziness. Due to its favorable safety profile and high selectivity, Levodropropizine has become a preferred choice in many international pharmacopoeias for treating acute and chronic coughs. It is often available in syrup, tablet, or capsule formulations, allowing for flexible dosing strategies tailored to patient needs. As a result, it remains a cornerstone in modern respiratory therapy, offering effective symptom control without the drawbacks associated with older antitussive medications.